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The majority of the fibroblast growth factor receptor 1-serotonin 1 A receptor (FGFR1-5-HT1AR) 
heterocomplexes in the hippocampus appeared to be located mainly in the neuronal networks 
and a relevant target for antidepressant drugs. Through a neurochemical and 
electrophysiological analysis it was therefore tested in the current study if astrocytic FGFR1-5-
HT1AR heterocomplexes also exist in hippocampus. They may modulate the structure and 
function of astroglia in the hippocampus leading to possible changes in the gamma oscillations. 
Localization of hippocampal FGFR1-5-HT1AR heterocomplexes in astrocytes was found using in 
situ proximity ligation assay combined with immunohistochemistry using glial fibrillary acidic 
protein (GFAP) immunoreactivity as a marker for astroglia. Acute i.c.v. treatment with 8-OH-
DPAT alone or together with basic fibroblast growth factor (FGF2) significantly increased FGFR1-
5-HT1AR heterocomplexes in the GFAP positive cells, especially in the polymorphic layer of the 
dentate gyrus (PoDG) but also in the CA3 area upon combined treatment. No other hippocampal 
regions were studied. Also, structural plasticity changes were observed in the astrocytes, 
especially in the PoDG region, upon these pharmacological treatments. They may also be of 
relevance for enhancing the astroglial volume transmission with increased modulation of the 
neuronal networks in the regions studied. The effects of combined FGF2 and 5-HT agonist 
treatments on gamma oscillations point to a significant antagonistic interaction in astroglial 
FGFR1-5-HT1AR heterocomplexes that may contribute to counteraction of the 5-HT1AR-
mediated decrease of gamma oscillations.  
 
